Rezdiffra (Resmetirom) International Purchase: What Women Need to Know Before Ordering

What Rezdiffra Actually Is and Why Women Develop MASH Differently

Rezdiffra is the first FDA-approved medication for metabolic dysfunction-associated steatohepatitis (MASH), formerly called NASH. It works as a thyroid hormone receptor beta (THR-beta) agonist, acting selectively on the liver to reduce fat accumulation and fibrosis without the cardiac and bone side effects of systemic thyroid hormone excess.

MASH is not a disease that affects men and women equally. Premenopausal women have lower rates of significant liver fibrosis than age-matched men, likely because estrogen exerts hepatoprotective effects by modulating lipid metabolism and reducing hepatic stellate cell activation. After menopause, that protection disappears. Postmenopausal women show fibrosis progression rates that approach or exceed those of men, and metabolic shifts including central adiposity, dyslipidemia, and insulin resistance all accelerate hepatic fat deposition.

How Estrogen Loss Changes Liver Fat

Estrogen regulates hepatic fatty acid oxidation through estrogen receptor alpha (ERalpha). When estrogen declines in perimenopause and menopause, hepatic fat uptake increases and mitochondrial beta-oxidation slows. A 2023 analysis of liver biopsy data found that women with surgically induced menopause had significantly faster MASH fibrosis progression than those with natural menopause, suggesting that the abruptness of estrogen loss, not just its absence, matters.

PCOS is another major driver. Women with PCOS have a 2.5-fold higher prevalence of MASH compared to BMI-matched controls because hyperinsulinemia, androgen excess, and dyslipidemia all prime the liver for fat accumulation and inflammation.

The MAESTRO-NASH Trial: How Many Women Were Enrolled

The key MAESTRO-NASH trial (NCT03900429) enrolled 966 patients with biopsy-confirmed MASH and F2 or F3 fibrosis. Women made up approximately 53 percent of the trial population, which is unusually representative for a liver disease trial. At 80 mg daily, resmetirom met its dual primary endpoints: MASH resolution without worsening fibrosis occurred in 25.9 percent of patients versus 14.2 percent on placebo, and fibrosis improvement by at least one stage occurred in 24.2 percent versus 14.2 percent on placebo. Sex-stratified responder analyses were not separately published in the primary paper, but Madrigal has stated that efficacy was consistent across sexes.

The International Purchase Question: What Is Legal and What Is Not

This is the question many women ask when they see the US list price. The direct answer is stark. There is no country outside the United States where resmetirom has received marketing authorization as of January 2026. The FDA granted Rezdiffra accelerated approval on March 14, 2024, based on surrogate histologic endpoints, with a confirmatory outcomes trial (MAESTRO-NASH OUTCOMES) ongoing. The European Medicines Agency had not issued a decision as of this writing, and Health Canada had not approved the drug.

Why "No Approval" Means Real Risk, Not Just Bureaucracy

When a medication has not been approved by a country's regulatory body, that country's pharmacies cannot legally dispense it. Online pharmacies operating in gray markets may list resmetirom, but those products carry risks that are not theoretical.

First, the supply chain is unverified. No independent body has confirmed the tablet's identity, potency, or absence of contaminants. Second, resmetirom has a specific pharmacological profile as a THR-beta agonist. Counterfeit or mislabeled thyroid-active compounds could produce hyperthyroidism, arrhythmia, or bone loss. Third, the drug requires baseline and interval monitoring including liver function tests, lipid panels, and thyroid-stimulating hormone levels to detect the dose-dependent LDL reduction and any hepatic signals. Ordering without that monitoring removes the safety net the trial was built around.

Personal Importation: The FDA's Rule and Its Real Limits

The FDA has a policy allowing personal importation of up to a 3-month supply of a foreign drug for personal use when no domestic alternative exists and the drug poses no unreasonable risk. Resmetirom does not qualify for this exception because a domestic product exists and is commercially available. The FDA's personal importation policy explicitly states that the agency generally does not allow importation of drugs that are approved in the US but obtained from foreign sources to save money.

Customs and Border Protection enforces this at the border. Packages containing prescription drugs without a valid US prescription can be seized. You would not be criminally prosecuted in most cases, but the shipment would be lost and your money gone.

What About Mexico, Canada, or India?

Mexico does not stock resmetirom because it has not been approved by COFEPRIS, Mexico's drug regulatory agency. Canadian pharmacies operating legally under Health Canada cannot dispense it for the same reason. Indian manufacturers produce many generics, but generic resmetirom is not yet legal anywhere because the compound is under patent protection (Madrigal holds patents extending into the 2030s) and no country has issued a compulsory license for it.

Some online services advertise "generics" of novel drugs before patents expire. These are not legitimate generics. They may be entirely different compounds, mislabeled products, or outright counterfeits.

How to Actually Pay Less for Rezdiffra in the United States

The list price of Rezdiffra is approximately $47,400 per year, but almost nobody pays that. Here are the real pathways, with specific details.

Madrigal's Patient Assistance Program

Madrigal Pharmaceuticals operates Madrigal One, a patient support program that includes a co-pay assistance card for commercially insured patients and a separate free drug program for uninsured or underinsured patients who meet income criteria. As of 2025, commercially insured patients may pay as little as zero dollars per month through the co-pay card, subject to eligibility. Income thresholds for the free drug program have not been publicly disclosed and change frequently. Call 1-844-901-7687 or have your prescriber's office contact the program directly.

Insurance Coverage and Prior Authorization

Most major commercial insurers and PBMs (pharmacy benefit managers) require prior authorization for Rezdiffra. A successful prior authorization typically needs:

• A liver biopsy report confirming MASH with F2 or F3 fibrosis
• Documentation of nonalcoholic etiology
• Evidence that lifestyle modification has been attempted
• A prescribing hepatologist or gastroenterologist (some insurers require a specialist, not a primary care provider)

Medicare coverage is available through Part D, but the specifics depend on the plan formulary. As of 2026, Rezdiffra is on the formulary of several major Part D plans at Tier 3 or Tier 4. The Medicare Extra Help (Low Income Subsidy) program can reduce out-of-pocket costs to a few dollars per month for qualifying women.

Medicaid coverage varies by state. Several states have not yet added Rezdiffra to their preferred drug lists. Your prescriber can submit a prior authorization with supporting clinical documentation to appeal a denial.

HSA and FSA Eligibility

Yes, Rezdiffra is HSA and FSA eligible. Prescription drugs that are FDA-approved and prescribed for a diagnosed medical condition qualify under IRS Publication 502, which governs medical expense deductions and tax-advantaged account use. You need a valid prescription from a licensed US provider and a diagnosis code on the pharmacy claim. Keep your receipt and the prescription label for your records. Your HSA or FSA debit card can be used directly at most retail and specialty pharmacies that dispense Rezdiffra.

If you use an HSA, the triple tax advantage (pre-tax contributions, tax-free growth, tax-free withdrawal for medical expenses) makes this one of the most efficient ways to pay out-of-pocket costs while you wait for insurance approval.

Specialty Pharmacy Access

Rezdiffra is dispensed through specialty pharmacies rather than standard retail chains. Madrigal's preferred specialty pharmacy network includes CVS Specialty, Walgreens Specialty, and several others. Your prescriber will typically submit to one of these. If you encounter barriers, ask your provider's office to contact Madrigal One for pharmacy routing assistance.

Pregnancy, Lactation, and Contraception: A Required Read

Resmetirom is contraindicated in pregnancy. This is not a precautionary statement based on missing data alone. Animal reproductive toxicology studies showed embryo-fetal toxicity at doses below the human therapeutic dose. The FDA prescribing information assigns resmetirom to a category consistent with known or suspected teratogenic risk and requires verification of pregnancy status before initiating treatment.

Before You Start: Pregnancy Testing and Contraception

The prescribing label requires a negative pregnancy test before the first dose. Women of reproductive potential must use effective contraception during treatment. The label does not specify a particular contraceptive method, but given the teratogenic signal from animal data, a highly effective method (hormonal contraception, IUD, or permanent sterilization) is appropriate rather than barrier methods alone.

For women with PCOS who are treating MASH and may be trying to conceive, this creates a real clinical tension. Resmetirom cannot be used during a conception attempt or pregnancy. If you are planning pregnancy, discuss timing with your hepatologist and your OB-GYN or reproductive endocrinologist. Fibrosis stage and rate of progression should inform whether deferring treatment is acceptable.

Lactation

Human data on resmetirom transfer into breast milk do not exist. The drug's lipophilicity and molecular weight suggest some transfer is possible, though the clinical significance is unknown. The FDA label recommends against breastfeeding during treatment. Women who are postpartum and wish to breastfeed should delay resmetirom initiation until they have weaned their infant.

Postpartum Considerations

Postpartum thyroiditis affects approximately 5 to 10 percent of women in the first year after delivery. Because resmetirom acts on thyroid hormone receptors, women with a history of postpartum thyroiditis or Hashimoto's thyroiditis should have thyroid function evaluated before starting treatment and monitored during it. The drug does not raise or lower serum thyroid hormone levels in a clinically meaningful way at therapeutic doses based on MAESTRO-NASH data, but pre-existing thyroid autoimmunity warrants baseline documentation.

Who Rezdiffra Is Right For and Who Should Wait

Rezdiffra's FDA indication is specific: adults with noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) confirmed by liver biopsy showing moderate to severe fibrosis (F2 or F3 on the METAVIR or CRN scoring system). It is not approved for:

• Simple steatosis (fatty liver without inflammation or fibrosis)
• F0 or F1 fibrosis
• Cirrhosis (F4)
• Alcohol-related liver disease
• Children or adolescents

Women Who Are Most Likely to Benefit

Postmenopausal women with F2 or F3 MASH represent the group with the greatest unmet need and, based on the biology described earlier, possibly the group with the fastest progression risk if untreated. Women with PCOS who have progressed to biopsy-confirmed MASH with significant fibrosis are also candidates, though no PCOS-specific subgroup analysis from MAESTRO-NASH has been published as of January 2026.

Women with hypothyroidism on levothyroxine should know that resmetirom does not replace thyroid hormone replacement. The two drugs act on different receptor populations (THR-beta in the liver versus systemic THR-alpha and THR-beta elsewhere). Hypothyroidism itself is associated with hepatic steatosis, and treating it adequately is a prerequisite before attributing liver fat purely to MASH. ACOG Practice Bulletin No. 223 on thyroid disease in pregnancy is the reference for managing hypothyroidism in reproductive-age women, though it predates resmetirom's approval and does not address the combination.

Women Who Should Not Use Rezdiffra Now

• Pregnant women or those attempting conception (see above)
• Breastfeeding women
• Women with cirrhosis (F4): not studied, not approved, and potentially harmful given that the drug's safety in decompensated liver disease is unknown
• Women whose liver disease is alcohol-related rather than metabolic
• Women with severe renal impairment: the label advises caution because pharmacokinetic data in severe CKD are limited

Monitoring Requirements: What Your Doctor Needs to Track

Rezdiffra is not a drug you start and forget. The MAESTRO-NASH protocol and the FDA label both require specific laboratory monitoring that women should understand before initiating.

Baseline Labs

Before starting, your provider should obtain: liver function tests (ALT, AST, bilirubin, alkaline phosphatase), a full lipid panel, TSH, fasting glucose or HbA1c, and a pregnancy test if you are of reproductive potential.

On-Treatment Monitoring

LDL cholesterol falls significantly on resmetirom. In MAESTRO-NASH, LDL-C decreased by approximately 16 to 19 percent from baseline at both doses over 52 weeks. This is generally beneficial, but if you are already on a statin at maximum dose, your lipid panel should be rechecked at 12 weeks to guide any statin adjustments.

ALT and AST typically decrease on resmetirom. A rise in transaminases on treatment should prompt evaluation for another cause such as drug-induced liver injury, biliary disease, or alcohol use.

The most common adverse events in MAESTRO-NASH were nausea (26.2 percent at 100 mg) and diarrhea (28.7 percent at 100 mg), both predominantly in the first 8 weeks. These were mostly mild to moderate. For women already managing GI symptoms from other medications (metformin for PCOS, for example), staggering doses and taking resmetirom with food may reduce GI burden.

Evidence Gaps Specific to Women

The trial enrolled a majority of women, which is a genuine strength. But several gaps remain.

Sex-stratified efficacy data from MAESTRO-NASH have not been published in peer-reviewed form as of this writing. The primary paper reported overall results. Women-specific fibrosis response rates, women-specific safety signals, and outcomes by menopausal status are not yet available. This matters because the biology of MASH differs by hormonal status, and a drug that modulates hepatic thyroid hormone signaling could theoretically interact differently in women with hypothyroidism, those on hormonal therapy, or those in active perimenopause.

The ongoing MAESTRO-NASH OUTCOMES trial is a confirmatory cardiovascular and liver outcomes study. Whether it will report sex-stratified results in adequate detail remains to be seen. Women who enroll in that trial contribute to the evidence base that the field needs.

Concurrent use of menopausal hormone therapy (MHT) and resmetirom has not been studied. Estrogen therapy improves hepatic steatosis in some women, and the theoretical interaction with a THR-beta agonist acting on the same hepatic metabolic pathways is uncharacterized. Until data exist, this is an area where shared decision-making with a hepatologist and menopause specialist is the appropriate standard.

A Note on Compounding and Telehealth Prescribing

Some telehealth platforms have offered compounded versions of GLP-1 drugs during shortage periods. A similar question will arise for resmetirom if access barriers persist. Compounded resmetirom is not currently legal in the United States. The FDA allows compounding of approved drugs under specific shortage or clinical need conditions, and resmetirom is not on the FDA drug shortage list. A compounding pharmacy that offers resmetirom would be operating outside the law, and the product would be unapproved and unregulated.

GLP-1 receptor agonists (semaglutide, tirzepatide) may reduce hepatic fat and are being studied in MASH. The ESSENCE trial of semaglutide in MASH reported histologic benefit. These are not substitutes for resmetirom in the specific approved population, but for women who cannot yet access resmetirom, optimizing GLP-1 therapy for concurrent obesity and metabolic disease is a reasonable adjunct strategy to discuss with your hepatologist.